Data Last Updated: Feb. 14, 2019 (Version 1.5)

NAACCR Item #3845: Grade Post Therapy

Start Column

1288

End Column

1288

Alignment

LEFT

Padding Character

' '

Documentation

Item # Length Source of Standard Year Implemented Version Implemented Year Retired Version Retired Column #
3845 1 NAACCR 2018 18 1288 - 1288

NAACCR XML: Tumor.gradePostTherapy

Description
This data item records the grade of a solid primary tumor that has been resected following neoadjuvant therapy. If AJCC staging is being assigned, the tumor must have met the surgical resection requirements in the AJCC manual.

Record the highest grade documented from the surgical treatment resection specimen of the primary site following neoadjuvant therapy.

For cases diagnosed January 1, 2018, and later, this data item, along with Grade Clinical and Grade Pathological, replaces NAACCR Data Item Grade [440] as well as SSF’s for cancer sites with alternative grading systems (e.g., breast [Bloom-Richardson], prostate [Gleason]).
Rationale
Grade is a measure of the aggressiveness of the tumor. Grade and cell type are important prognostic indicators for many cancers. For some sites, grade is required to assign the post-neoadjuvant stage group.

For those cases that are eligible AJCC staging, the recommended grading system is specified in the AJCC Chapter. The AJCC Chapter-specific grading systems (codes 1-5) take priority over the generic grade definitions (codes A-E, L, H, 9). For those cases that are not eligible for AJCC staging, if the recommended grading system is not documented, the generic grade definitions would apply.
Codes (Refer to the most recent version of the SSDI Manual for additional site-specific instructions)
Each Site-Specific Data Item (SSDI) applies only to selected primary sites, histologies, and years of diagnosis. Depending on applicability and standard-setter requirements, SSDIs may be left blank. Leave blank for cases diagnosed prior to 2018.